/

Società

Pe

Non verificato

PeproMene Bio, Inc.

Di cosa scriviamo

BiologiaEcologia/Salute ambientaleEventiFarmaceuticaSanità

3 comunicati stampa

Guarda tutti i comunicati

Press Release cover image

28/05/2026

Salute

Fitness

Fiere

Eventi

Medicina - Varie

Ecologia/Salute ambientale

Agricoltura

PeproMene Bio Announces Oral Presentation at EHA 2026 Highlighting Favorable Safety and Durable Responses with PMB-CT01 (BAFF-R CAR T-Cell Therapy) in B-cell Lymphomas, Including After Prior CD19 CAR T-Cell Failure

Fonte

PeproMene Bio, Inc.

Emittente

1.00

0

20/05/2025

Farmaceutica

Sanità

Biologia

PeproMene Bio, Inc. and the Institute for Follicular Lymphoma Innovation (IFLI) Announce The First Follicular Lymphoma (FL) Patient Treated with BAFF-R Targeting CAR-T Cells (PMB-CT01) Achieves a Complete Response

Fonte

PeproMene Bio, Inc.

Emittente

1.00

0

Press Release cover image

07/08/2024

Farmaceutica

Sanità

Biologia

PeproMene Bio announced study demonstrating strong polyfunctionality of novel chimeric antigen receptor (CAR) T cells

Fonte

PeproMene Bio, Inc.

Emittente

1.00

0

Seguaci

0

Compatibilità

0